Identification of genetic markers for prostatic cancer progression

Laboratory Investigation

Volumn 80, Issue 6, 2000, Pages 931-942

  Alers, Janneke C ^a,b   Rochat, Jenneke ^a   Krijtenburg, Pieter Jaap ^a   Hop, Wim C J ^a   Kranse, Ries ^b   Rosenberg, Carla ^c   Tanke, Hans J ^c   Schröder, Fritz H ^b   Van Dekken, Herman ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CHROMOSOME 13Q; CHROMOSOME 16Q; CHROMOSOME 18Q; CHROMOSOME 6Q; CHROMOSOME 7P; CHROMOSOME 8P; CHROMOSOME 8Q; CHROMOSOME ARM; CHROMOSOME LOSS; CONTROLLED STUDY; GENE AMPLIFICATION; GENETIC MARKER; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0033936835     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3780096     Document Type: Article

References (74)

1. Alcaraz A, Takahashi S, Brown JA, Herath JF, Bergstralh EJ, Larson-Keller JJ, Lieber MM, and Jenkins RB (1994). Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res 54:3998-4002.
2. Alers JC, Krijtenburg PJ, Hop WCJ, Bolle WA, Schröder FH, van der Kwast ThH, Bosman FT, and van Dekken H (1998). Longitudinal evaluation of cytogenetic aberrations in prostatic cancer: Tumours that recur in time display an intermediate genetic status between non-persistent and metastatic tumours. J Pathol 185:273-283.
3. Alers JC, Krijtenburg PJ, Rosenberg C, Hop WC, Verkerk AM, Schröder FH, van der Kwast TH, Bosman FT, and van Dekken H (1997). Interphase cytogenetics of prostatic tumor progression: Specific chromosomal abnormalities are involved in metastasis to the bone. Lab Invest 77:437-448.
4. Alers JC, Rochat J, Krijtenburg PJ, van Dekken H, Raap AK, and Rosenberg C (1999). Universal linkage system (ULS): An improved method for labeling archival DNA for comparative genomic hybridization. Genes Chromosomes Cancer 25: 301-305.
5. Alers JC and van Dekken H (1996). Interphase cytogenetic analysis of solid tumors by non-isotopic DNA in situ hybridization (Review). Prog Histochem Cytochem 31:1-133.
6. Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, and Lee WH (1990). Promoter deletion and loss of retinoblastoma expression in human prostate carcinoma. Proc Natl Acad Sci USA 87:7762-7766.
7. Bova GS, Carter B, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC, and Isaacs WB (1993). Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 53:3869-3873.
8. Brothman AR, Maxwell TM, Cui J, Deubler DA, and Zhu XL (1999). Chromosomal clues to the development of prostate tumors (Review). Prostate 38:303-312.
9. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, and Kallioniemi OP (1999). Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res 59:803-806.
10. Carter HB and Coffey DS (1990). The prostate: An increasing medical problem. Prostate 16:39-48.
11. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, and Jensen RH (1996). Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization. Cancer Res 56:3091-3102.
12. Cooney KA, Wetzel JC, Consolino CM, and Wojno KJ (1996a). Identification and characterization of proximal 6q deletions in prostate cancer. Cancer Res 56:4150-4153.
13. Cooney KA, Wetzel JC, Meravjer SD, Macoska JA, Singleton TP, and Wojno KJ (1996b). Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res 56:1142-1145.
14. Craft N, Shostak Y, Carey M, and Sawyers CL (1999). A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280-285.
15. Cunningham JM, Shan A, Wick MJ, McDonnell SK, Schaid DJ, Tester DJ, Qian J, Takahashi S, Jenkins RB, Bostwick DG, and Thibodeau SN (1996). Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res 56:4475-4482.
16. Dahiya R, McCarville J, Hu W, Lee C, Chui RM, Kaur G, and Deng G (1997). Chromosome 3p24-26 and 3p22-12 loss in human prostatic adenocarcinoma. Int J Cancer 71:20-25.
17. Dong JT, Sipe TW, Hyytinen ER, Li CL, Heise C, McClintock DE, Grant CD, Chung LW, and Frierson HF Jr (1998). PTEN/ MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene 17:1979-1982.
18. Eagle LR, Yin X, Brothman AR, Williams BJ, Atkin NB, and Prochownik EV (1995). Mutation of the MXI1 gene in prostate cancer. Nat Genet 9:249-255.
19. Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, Zhuang Z, Bostwick DG, Liotta LA, and Linehan WM (1995). Allelic loss on chromosome 8p12-p21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 55:2959-2962.
20. Filippova GN, Lindblom A, Meincke LJ, Klenova EM, Neiman PE, Collins SJ, Doggett NA, and Lobanenkov W (1998). A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletion in breast and prostate cancers. Genes Chromosomes Cancer 22:26-36.
21. Gao X, Porter AT, and Honn KV (1997). Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications (Review). Adv Exp Med Biol 407:41-53.
22. Gao X, Zacharek A, Grignon DJ, Sakr W, Powell IJ, Porter AT, and Honn KV (1995). Localization of potential tumor suppressor loci to a < 2 Mb region on chromosome 17q in human prostate cancer. Oncogene 11:1241-1247.
23. Gittes RF (1991). Carcinoma of the prostate. N Eng J Med 324:236-245.
24. Gleason DF (1992). Histologic grading of prostate cancer. Hum Pathol 23:273-279.
25. Gray IC, Philips SMA, Lee SJ, Neoptolemos JP, Weissenbach J, and Spurr NK (1995). Loss of chromosomal region 10q23-q25 in prostate cancer. Cancer Res 55:4800-4803.
26. He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, Meissner PS, Curtis RT, Shell BK, Bostwick DG, Tindall DJ, Gelmann EP, Abate-Shen C, and Carter KC (1997). A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 43:69-77.
27. Hermanek P, Hutter RVP, Sobin LH, Wagner G, and Wittekind CH, editors (1997). TNM atlas: Illustrated guide to the TNM/pTNM classification of malignant tumors, 4th ed. Berlin: Springer Verlag, 272-280.
28. Huang SF, Xiao S, Renshaw AA, Loughlin KR, Hudson TJ, and Fletcher JA (1996). Fluorescence in situ hybridization evaluation of chromosome deletion patterns in prostate cancer. Am J Pathol 149:1565-1573.
29. Hyytinen ER, Frierson HF Jr, Boyd JC, Chung LW, and Dong JT (1999). Three distinct regions of allelic loss at 13q14, 13q21-q22, and 13q33 in prostate cancer. Genes Chromosomes Cancer 25:108-114.
30. Ishii H, Baffa R, Numata SI, Murakumo Y, Rattan S, Inoue H, Mori M, Fidanza V, Alder H, and Croce CM (1999). The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors. Proc Natl Acad Sci USA 96:3928-3933.
31. Isola J, DeVries S, Chu L, Ghazvini S, and Waldman F (1994). Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol 145:1301-1308.
32. Jenkins RB, Qian J, Lee HK, Huang H, Hirasawa K, Bostwick DG, Proffitt J, Wilber K, Lieber MM, Liu W, and Smith DI (1998). A molecular cytogenetic analysis of 7q31 in prostate cancer. Cancer Res 58:759-766.
33. Jenkins RB, Qian J, Lieber MM, and Bostwick DG (1997). Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57:524-531.
34. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, and Pinkel D (1992). Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258:818-821.
35. Kirchhoff M, Gerdes T, Rose H, Maahr J, Ottesen AM, and Lundsteen C (1998). Detection of chromosomal gains and losses in comparative genomic hybridization analysis based on standard reference intervals. Cytometry 31:163-173.
36. Knuutila S, Björkqvist AM, Autio K, Tarkkanen M, Wolf M, Monni O, Szymanska J, Larramendy ML, Tapper J, Pere H, El-Rifai W, Hemmer S, Wasenius VM, Vidgren V, and Zhu Y (1998). DNA copy number amplifications in human neoplasms: Review of comparative genomic hybridization studies (Review). Am J Pathol 152:1107-1123.
37. Komiya A, Suzuki H, Ueda T, Yatani R, Emi M, Ito H, and Shimazaki J (1996). Allelic losses at loci on chromosome 10 are associated with metastasis and progression of human prostate cancer. Genes Chromosomes Cancer 17:245-253.
38. Kupelian P, Katcher J, Levin H, Zippe C, and Klein E (1996). Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 48: 249-260.
39. Landis SH, Murray T, Bolden S, and Wingo PA (1998). Cancer statistics, 1998. CA Cancer J Clin 48:6-29.
40. Larramendy ML, El-Rifai W, and Knuutila S (1998). Comparison of fluorescein isothiocyanate- and Texas red-conjugated nucleotides for direct labeling in comparative genomic hybridization. Cytometry 31:174-179.
41. Latil A, Cussenot O, Fournier G, Driouch K, and Lidereau R (1997). Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: Identification of three independent regions. Cancer Res 57:1058-1062.
42. Li C, Berx G, Larsson C, Auer G, Aspenblad U, Pan Y, Sundelin B, Ekman P, Nordenskjöld M, van Roy F, and Bergerheim USR (1999). Distinct deleted regions on chromosome segment 16q23-24 associated with metastases in prostate cancer. Genes Chromosomes Cancer 24:175-182.
43. Li C, Larsson C, Futreal A, Lancaster J, Phelan C, Aspenblad U, Sundelin B, Liu Y, Ekman P, Auer G, and Bergerheim USR (1998). Identification of two distinct deleted regions on chromosome 13 in prostate cancer. Oncogene 16:481-487.
44. Macoska JA, Trybus TM, Sakr WA, Wolf MC, Benson PD, Powell IJ, and Fontes JE (1994). Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer. Cancer Res 54:3824-3830.
45. Melamed J, Einhorn JM, and Ittmann MM (1997). Allelic loss on chromosome 13q in human prostate carcinoma. Clin Cancer Res 3:1867-1872.
46. Nowell PC (1976). The clonal evolution of tumor cell populations. Science 194:23-28.
47. Nupponen NN, Kakkola L, Koivisto P, and Visakorpi T (1998). Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 153:141-148.
48. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, and Chung LW (1995). C-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 154: 293-298.
49. Perinchery G, Bukurov N, Nakajima K, Chang J, Li LC, and Dahiya R (1999). High frequency of deletion on chromosome 9p21 may harbor several tumor-suppressor genes in human prostate cancer, Int J Cancer 83:610-614.
50. Potosky AL, Miller BA, Albertsen PC, and Kramer BS (1995). The role of increasing detection in the rising incidence of prostate cancer. JAMA 273:548-552.
51. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, and Witte ON (1998). Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 95:1735-1740.
52. Ross JS, Sheehan C, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman R Jr, Fisher HAG, Rifkin MD, and Muraca PJ (1997). Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 79:2162-2170.
53. Saric T, Brkanac Z, Troyer DA, Padalecki SS, Sarosdy M, Williams K, Abadesco L, Leach RJ, and O'Connell P (1999). Genetic pattern of prostate cancer progression, Int J Cancer 81:219-224.
54. Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ, and Jenkins RB (1999). Clinical significance of alterations of chromosome 8 in high-grade, advanced, non-metastatic prostate carcinoma. J Natl Cancer Inst 91:1574-1580.
55. Scardino PT, Weaver R, and Hudson MA (1992). Early detection of prostate cancer. Hum Pathol 23:211-222.
56. Schröder FH, van der Maas P, Beemsterboer P, Boeken Kruger A, Hoedemaeker R, Rietbergen J, and Kranse R (1998). Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 90:1817-1823.
57. Schwartz S Jr, Caceres C, Morote J, De Torres I, Rodriguez-Vallejo JM, Gonzalez J, and Reventes J (1999). Gain of the relative genomic content of erbB-1 and erbB-2 in prostate carcinoma and their association with metastasis, Int J Oncol 14:367-371.
58. Smith JR, Freije D, Carpten JD, Grönberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, and Isaacs WB (1996). Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274:1371-1374.
59. Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, and Jenkins RB (1994). Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization. Cancer Res 54:3574-3579.
60. Takahashi S, Shan AL, Ritland SR, Delacey KA, Bostwick DG, Lieber MM, Thibodeau SN, and Jenkins RB (1995). Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res 55:5115-5119.
61. Uchida T, Wang C, Sato T, Gao J, Takashima R, Irie A, Ohori M, and Koshiba K (1999). BRCA1 gene mutation and loss of heterozygosity on chromosome 17q21 in primary prostate cancer, Int J Cancer 84:19-23.
62. Ueda T, Emi M, Suzuki H, Komiya A, Akakura K, Ichikawa T, Watanabe M, Shiraishi T, Masai M, Igarashi T, and Ito H (1999). Identification of a 1-cM region of common deletion on 13q14 associated with human prostate cancer. Genes Chromosomes Cancer 24:183-190.
63. Ueda T, Komiya A, Emi M, Suzuki H, Shiraishi T, Yatani R, Masai M, Yasuda K, and Ito H (1997). Allelic losses on 18q21 are associated with progression and metastasis in human prostate cancer. Genes Chromosomes Cancer 20:140-147.
64. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HFM, Oosterhof GON, DeBruyne FMJ, and Schalken JA (1994). Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54:3929-3933.
65. Van Alewijk DC, Van der Weiden MM, Eussen BJ, Van den Andel-Thijssen LD, Ehren-van Eekelen CC, Konig JJ, van Steenbrugge GJ, Dinjens WN, and Trapman J (1999). Identification of a homozygous deletion at 8p12-21 in a human prostate cancer xenograft. Genes Chromosomes Cancer 24:119-126.
66. van Dekken H, Rosenberg C, Krijtenburg PJ, and Alers JC (1997). Interphase cytogenetics and comparative genomic hybridization of human epithelial cancers and precursor lesions. Histochem Cell Biol 108:419-430.
67. Van den Berg C, Guan XY, von Hoff D, Jenkins R, Bittner M, Griffin C, Kallioniemi O, Visakorpi T, McGill J, Herath J, Epstein J, Sarosdy M, Meltzer P, and Trent J (1995). DNA sequence amplification in human prostate cancer identified by chromosome microdissection: Potential prognostic implications. Clin Cancer Res 1:11-18.
68. Virgin JB, Hurley PM, Nahhas FA, Bebchuk KG, Mohamed AN, Sakr WA, Bright RK, and Cher ML (1999). Isochromosome 8q formation is associated with 8p loss of heterozygosity in a prostate cancer cell line. Prostate 41:49-57.
69. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, and Kallioniemi OP (1995a). In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet, 9:401-406.
70. Visakorpi T, Kallioniemi AH, Syvänen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, and Kallioniemi OP (1995b). Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 55:342-347.
71. Vlietstra RJ, Van Alewijk DC, Hermans KG, van Steenbrugge GJ, and Trapman J (1998). Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58: 2720-2723.
72. Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, Duray PH, Liotta LA, Emmert-Buck MR, and Linehan WM (1996). Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-p21. Cancer Res 56:2411-2416.
73. Weizmann Institute of Science Genome and Bioinformatics (2000). Weizmann Institute of Science, Israel, (http:// bioinfo.weizmann.ac.il)
74. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, Bova GS, Walsh P, Isaacs W, Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi OP, Berry R, Schaid D, French A, McDonnell S, Schroeder J, Blute M, Thibodeau S, Grönberg H, Emanuelsson M, Damber JE, Bergh A, Jonsson BA, Smith J, Bailey-Wilson J, Carpten J, Stephan D, Gillanders E, Amundson I, Kainu T, Freas-Lutz D, Baffoe-Bonnie A, Van Aucken A, Sood R, Collins F, Brownstein M, and Trent J (1998). Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 20:175-179.